Possible immunological events and their pivotal role in disease progression during sepsis: A review

Awanindra Dwivedi , Prateek Kumar Singh , Zari Anjum , Awadhesh Kumar Yadav , Ravi Ranjan , Vijayananth Pavadai , Vinay Kumar Garg , Atul Goel
{"title":"Possible immunological events and their pivotal role in disease progression during sepsis: A review","authors":"Awanindra Dwivedi ,&nbsp;Prateek Kumar Singh ,&nbsp;Zari Anjum ,&nbsp;Awadhesh Kumar Yadav ,&nbsp;Ravi Ranjan ,&nbsp;Vijayananth Pavadai ,&nbsp;Vinay Kumar Garg ,&nbsp;Atul Goel","doi":"10.1016/j.acci.2024.05.010","DOIUrl":null,"url":null,"abstract":"<div><div>Study of possible physiological events leading to progression of sepsis, i.e., inflammation, coagulation–anticoagulation balance and immunosuppression which have been addressed by new therapeutic targets for these metabolic pathways and thereby, evolution of drugs has better therapeutic potential than the traditional ones. Online database and printed material were searched using relevant keywords. Collected literature was scrutinized for related information with special reference to the objective. These drug molecules have either been approved for treatment of human subjects or these are under evaluation for therapeutic potential on human subjects or animal models. Surviving Sepsis Campaign guidelines include recommendations for recognition and early care, source diagnosis and treatment of infection, hemodynamic care, ventilation and additional therapeutic treatment recommendations. Advancements in these treatment strategies have reduced the mortality yet there is need for implementation of genomic and proteomic<span> analysis techniques for better results. Smaller molecules should be preferred as therapeutic agents because of having less immunogenicity; smaller size is suitable for better tissue penetration.</span></div></div>","PeriodicalId":100016,"journal":{"name":"Acta Colombiana de Cuidado Intensivo","volume":"24 4","pages":"Pages 398-403"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Colombiana de Cuidado Intensivo","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0122726224000429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Study of possible physiological events leading to progression of sepsis, i.e., inflammation, coagulation–anticoagulation balance and immunosuppression which have been addressed by new therapeutic targets for these metabolic pathways and thereby, evolution of drugs has better therapeutic potential than the traditional ones. Online database and printed material were searched using relevant keywords. Collected literature was scrutinized for related information with special reference to the objective. These drug molecules have either been approved for treatment of human subjects or these are under evaluation for therapeutic potential on human subjects or animal models. Surviving Sepsis Campaign guidelines include recommendations for recognition and early care, source diagnosis and treatment of infection, hemodynamic care, ventilation and additional therapeutic treatment recommendations. Advancements in these treatment strategies have reduced the mortality yet there is need for implementation of genomic and proteomic analysis techniques for better results. Smaller molecules should be preferred as therapeutic agents because of having less immunogenicity; smaller size is suitable for better tissue penetration.
脓毒症期间可能发生的免疫事件及其在疾病进展中的关键作用:综述
研究导致败血症进展的可能生理事件,即炎症、凝血-抗凝血平衡和免疫抑制,这些代谢途径的新治疗靶点已经解决,因此,药物的演变比传统药物具有更好的治疗潜力。使用相关关键词搜索了在线数据库和印刷材料。对收集到的文献进行了仔细研究,以了解相关信息,特别是与目标相关的信息。这些药物分子要么已被批准用于治疗人类受试者,要么正在对人类受试者或动物模型的治疗潜力进行评估。败血症生存运动指南包括识别和早期护理、感染源诊断和治疗、血液动力学护理、通气和其他治疗建议。这些治疗策略的进步降低了死亡率,但仍需采用基因组和蛋白质组分析技术以取得更好的效果。由于免疫原性较低,应优先选择小分子药物作为治疗药物;较小的体积适合更好地渗透组织。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信